IntelliPharmaCeutics International (TSXV:IPCI) 3-Year Revenue Growth Rate : -75.90% (As of Aug. 2023)

View and export this data going back to 1999. Start your Free Trial

What is IntelliPharmaCeutics International 3-Year Revenue Growth Rate?

IntelliPharmaCeutics International's Revenue per Share for the three months ended in Aug. 2023 was C$0.00.

During the past 12 months, IntelliPharmaCeutics International's average Revenue per Share Growth Rate was 825.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was -75.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of IntelliPharmaCeutics International was 232.90% per year. The lowest was -81.20% per year. And the median was -30.05% per year.

Competitive Comparison of IntelliPharmaCeutics International's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, IntelliPharmaCeutics International's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IntelliPharmaCeutics International's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's 3-Year Revenue Growth Rate falls into.

IntelliPharmaCeutics International 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

IntelliPharmaCeutics International (TSXV:IPCI) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

IntelliPharmaCeutics International 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

IntelliPharmaCeutics International (TSXV:IPCI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (TSXV:IPCI) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

IPCIF:USA I4AA:Germany

Address

30 Worcester Road, Toronto, ON, CAN, M9W 5X2

Website

https://www.intellipharmaceutics.com

IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.

IntelliPharmaCeutics International (TSXV:IPCI) Headlines

No Headlines